<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156426">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01930292</url>
  </required_header>
  <id_info>
    <org_study_id>Debio 1143-103</org_study_id>
    <nct_id>NCT01930292</nct_id>
  </id_info>
  <brief_title>Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies</brief_title>
  <official_title>A Phase I Study to Evaluate the Safety and Determine the Maximum Tolerated Dose (MTD) of Debio 1143 Combined With Carboplatin and Paclitaxel in Patients With Squamous Non-Small Cell Lung Cancer (NSCLC), Platinum-refractory Ovarian Cancer, and Basal-like/Claudin Low Triple Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Debiopharm International SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Debiopharm International SA</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the MTD of Debio 1143 when administered in combination with full doses of
      paclitaxel and carboplatin in patients with squamous NSCLC, Pt-refractory ovarian cancer,
      and basal-like/claudin low TNBC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence rate of dose limiting toxicities (DLTs) of Debio1143 in combination with Carboplatin and Paclitaxel</measure>
    <time_frame>Approximately 18 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The dose escalation part of the study will be guided by a well-established statistical method/model to estimate the maximum tolerated dose(s) and/or the recommended dose for expansion (RDE). Safety(incidence and nature of DLTs), pharmacokinetic and pharmacodynamic data will guide dose escalation decisioins.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of Debio 1143 combination at the recommended dose (RDE)for expansion</measure>
    <time_frame>Every 21 days from baseline visit to 28 days after study drug discontinuation</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>This will be assessed by looking at the number of Adverse Events (AEs), serious AEs (SAEs) changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions and reductions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration of Inhibition Apoptosis Protein (IAP)</measure>
    <time_frame>Cycle 1: every day for 5 days, then at day 8 and day 15</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time vs. concentration profile of Debio 1143, Carboplatin and Paclitaxel</measure>
    <time_frame>Every 21 days for up to 6 cycles</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Plasma concentration versus time profiles. Plasma PK parameters will be used to characterize the PK profiles of the combination of Debio 1143 with Carboplatin and Paclitaxel</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall response rate</measure>
    <time_frame>Every 42 days from the date of baseline visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of preliminary antitumor activity of the combination of Debio 1143 with Carboplatin and Paclitaxel ; Overall response rate = complete response + partial response</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Debio 1143, Paclitaxel, Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants received oral Debio1143 once daily for 5 days every 21 days in combination with Paclitaxel (175mg/m2 on Day 1 every 21-day) and Carboplatin (AUC of 6 mg.min/mL on Day 1 every 21-day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Debio 1143</intervention_name>
    <arm_group_label>Debio 1143, Paclitaxel, Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Debio 1143, Paclitaxel, Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Debio 1143, Paclitaxel, Carboplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female ≥18 years of age.

          2. Willing and able to sign written informed consent;

          3. Histologically confirmed diagnosis of:

               -  Squamous NSCLC candidate for paclitaxel and carboplatin chemotherapy,

               -  Platinum-refractory primary or secondary ovarian cancer, defined as clinical
                  recurrences that takes place within 6 months of completion of a Pt-containing
                  regimen (http://www.cancer.gov/cancertopics/pdq/treatment/ovarianepithelial)

               -  TNBC basal-like and claudin low subtypes candidate for paclitaxel and
                  carboplatin chemotherapy.

          4. Availability of pre-treatment tumour sample (biopsy or tumour block);

          5. Advanced or metastatic disease;

          6. Measurable disease by the RECIST criteria;

          7. QTcF interval ≤ 450 milliseconds;

          8. Negative Hepatitis B and Hepatitis C testing:

               -  Hepatitis B screening tests: HepB sAg, Anti-HepB sAg, Anti-HepB core IgG,

               -  Hepatitis C screening test: HCV-RNA.

          9. Women of child-bearing potential:

               -  Negative pregnancy test at screening;

               -  Agreement to use appropriate contraception methods from study entry to 6 months
                  after the last day of treatment.

         10. Male patients agree to use contraception methods from study entry to 6 months after
             the last day of treatment;

         11. ECOG performance score 0 or 1;

         12. Subjects must have adequate haematological, renal, and hepatic function: calculated
             creatinine clearance ≥ 50 mL/min as determined by the modified method of Cockcroft
             and Gault or by the EDTA method; ANC ≥ 1500/μL, platelets ≥ 100000/μL, Hb ≥ 9 gm/dL
             (5 mmol/L), AST and ALT less than 4 times the ULN; total bilirubin ≤ 2.0 mg/dL.

         13. LVEF within the institutional normal ranges as measured by ECHO or MUGA scan;

         14. Able to swallow whole capsules with water at study inclusion;

         15. Life expectancy of at least 3 months in the best judgment of the Investigator;

         16. No prior treatment with IAP inhibitors;

         17. No use or requirement for use of aspirin or aspirin containing products with &gt; 81 mg
             of aspirin per day;

         18. No history of gastrointestinal bleeding within 1 year;

         19. No active rheumatoid arthritis, active inflammatory bowel disease, chronic infections
             or any other disease or condition associated with chronic inflammation.

        Exclusion Criteria:

          1. Suitable for any curative treatment;

          2. Unresolved ≥ Grade 2 toxicity from previous treatment;

          3. Symptomatic brain metastases;

          4. Concomitant use of strong inducers or inhibitors of CYPs 2C8 and 3A4;

          5. Gastro-intestinal disorders that could affect drug absorption (including, but not
             limited to, major abdominal surgery, significant bowel obstruction, ulcerative
             colitis, Crohn's disease);

          6. Concurrent treatment with any other systemic anti-cancer therapy that is not
             specified as part of the protocol regimen;

          7. Concomitant treatment with any drug on the prohibited medication list (provided
             separately);

          8. Subjects with known history of uncontrolled or symptomatic angina, arrhythmias or
             congestive heart failure;

          9. History of another malignancy within the last 5 years, with the exception of
             completely resected basal or squamous cell skin cancer, or successfully treated
             in-situ carcinoma. History of non-invasive lesion or in-situ carcinoma, including in
             the head and neck region that was successfully treated with surgery, photodynamics or
             laser, will be permitted;

         10. Peripheral neuropathy ≥ grade 2;

         11. If female, pregnant or lactating;

         12. History of allergic reactions to appropriate antiemetics (e.g. 5-HT3 antagonists) to
             be administered with chemotherapy;

         13. The Investigator considers the subject unfit for the study as a result of the medical
             interview, physical examinations, or screening investigations.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Pierre Delord, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Institut Claudius Regaud, Toulouse, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudio Zanna, MD</last_name>
    <phone>+41213210111</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christian Aeschlimann, MS</last_name>
    <phone>+41213210111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Isambert, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas Isambert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Ray-Coquard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Isabelle Ray-Coquard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75248</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe Le Tourneau, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe Le Tourneau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>31052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Pierre Delord, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Pierre Delord, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.debiopharm.com</url>
    <description>Site Debiopharm SA</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
